Trial Profile
BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs PRG 1801 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Pregene ShenZhen Biotechnology
- 08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 13 May 2021 Results (n=34) presented in a Dr Reddys Laboratories Media Release.